Pfizer is returning to Neurocrine Biosciences the development and marketing rights for Indiplon, a medicine in development to treat insomnia. This includes both the collaboration to develop and co-market Indiplon in the U.S. as well as Pfizer’s exclusive license to develop and market Indiplon outside of the U.S. As a result, Neurocrine will reacquire all worldwide rights for indiplon and will develop indiplon for approval and commercialization. Neurocrine will meet with the FDA to fin...